2020
DOI: 10.1016/j.jvir.2019.09.026
|View full text |Cite
|
Sign up to set email alerts
|

CT-Guided Percutaneous Drainage Catheter Placement in the Abdomen and Pelvis: Predictors of Outcome and Protocol for Follow-up

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 16 publications
0
4
0
Order By: Relevance
“…CT-guided drainage was performed using standard techniques [ 28 , 29 ] covered by internal standard operating procedures. The ideal skin entry site was determined using planning scans with a radiopaque grid placed on the patient’s skin.…”
Section: Methodsmentioning
confidence: 99%
“…CT-guided drainage was performed using standard techniques [ 28 , 29 ] covered by internal standard operating procedures. The ideal skin entry site was determined using planning scans with a radiopaque grid placed on the patient’s skin.…”
Section: Methodsmentioning
confidence: 99%
“…1,20,49,53,56,57 Patients with an improving and uncomplicated clinical course and decreasing catheter output (e.g., <10 mL/day) typically need no follow-up imaging. 19,[57][58][59] However, repeated cross-sectional imaging may be advised before catheter removal to confirm correct catheter positioning and resolution of the collection in patients with persistent fever/symptoms or high drain output. 49,57,58,[60][61][62] For example, a recent study conducted by Sari et al showed a low rate (0.8%) of abscess recurrence if the catheter is removed without routine imaging when drainage is less than 10 mL/day for at least 2 days, and the patient is clinically stable.…”
Section: Catheter Carementioning
confidence: 99%
“…The management of oncological patients has changed profoundly and, although the main goal is overall survival (OS), new knowledge of the molecular cancer profile and the development of new pharmacologic treatments has led to the use of surrogate end-points to measure interim treatment efficacy [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ] related to the disease setting, including disease-free (DF), recurrence-free (RF), and progression-free survival (PFS) [ 8 , 9 , 10 , 11 , 12 ]. In this context, interventional radiology (IR), especially ablation treatment, is one of the most rapidly growing areas in oncology [ 13 , 14 , 15 , 16 ]. Its success is essentially due to the minimally invasive nature of the treatment with lower complication rates and superior toxicity profiles, and often with comparable or superior mid- and long-term oncologic outcomes compared to conventional therapies, such as surgical procedures or systemic treatments [ 17 , 18 , 19 , 20 ].…”
Section: Introductionmentioning
confidence: 99%